Arpida (SIX: ARPN) is a biopharmaceutical company headquartered in Reinach, near Basel, Switzerland with operations in Switzerland and the USA. It focuses on novel drugs that seek to overcome the growing problem of microbial resistance. Arpida's leading product candidate is intravenous iclaprim, an antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).